Feb. 26 at 3:57 PM
Former scientist who worked at a genomics company here.
After evaluating the different CRISPR/gene editing companies, I’m most inclined to invest in
$PRME . Although their editing efficiency is low (it can also be optimized), they have nearly double the addressable genetic disease opportunities that BEAM does, with fewer (almost undetectable) off target effects.
I see having nearly unlimited opportunities with a pristine safety profile positions it above competitors like
$NTLA ,
$EDIT ,
$BEAM,
$CRSP , especially in leu of the Intellia death and their relatively tiny market cap.
